Keith Flaherty
#55,975
Most Influential Person Now
American medical researcher
Keith Flaherty's AcademicInfluence.com Rankings
Keith Flahertyphilosophy Degrees
Philosophy
#3965
World Rank
#6308
Historical Rank
#1208
USA Rank
Logic
#1530
World Rank
#2305
Historical Rank
#451
USA Rank
Download Badge
Philosophy
Keith Flaherty's Degrees
- Doctorate Medicine University of Pennsylvania
- PhD Molecular Biology University of Pennsylvania
Why Is Keith Flaherty Influential?
(Suggest an Edit or Addition)According to Wikipedia, Keith Flaherty is Director of Clinical Research at the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School. He was previously a professor of medicine at the University of Pennsylvania. He is known for his research on targeted therapies for cancer, and in particular for his work on the melanoma drug vemurafenib. In 2013, Massachusetts General Hospital partnered with AstraZeneca to partner Flaherty's research into developing a formula to identify vulnerabilities of tumors with AstraZeneca's library of drugs.
Keith Flaherty's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Improved survival with vemurafenib in melanoma with BRAF V600E mutation. (2011) (5546)
- Final version of 2009 AJCC melanoma staging and classification. (2009) (4419)
- Inhibition of mutated, activated BRAF in metastatic melanoma. (2010) (3502)
- Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq (2016) (2825)
- Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. (2012) (2458)
- Genomic Classification of Cutaneous Melanoma (2015) (2143)
- Improved overall survival in melanoma with combined dabrafenib and trametinib. (2015) (2115)
- Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. (2012) (2035)
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma (2010) (1645)
- Improved survival with MEK inhibition in BRAF-mutated melanoma. (2012) (1601)
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion (2012) (1516)
- Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. (2014) (1496)
- Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual (2017) (1458)
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) (2011) (1296)
- Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group (2012) (1230)
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial (2015) (1097)
- Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma (2018) (981)
- Targeted agents and immunotherapies: optimizing outcomes in melanoma (2017) (867)
- Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. (2006) (843)
- Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine (2017) (804)
- EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. (2012) (798)
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma (2013) (796)
- Mechanisms of resistance to immune checkpoint inhibitors (2018) (792)
- Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. (2014) (792)
- COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation (2010) (778)
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. (2019) (692)
- Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. (2010) (682)
- Phase II trial of sorafenib in advanced thyroid cancer. (2008) (670)
- Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis (2006) (645)
- Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. (2011) (616)
- RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. (2012) (610)
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. (2018) (577)
- SARS-CoV-2 viral load is associated with increased disease severity and mortality (2020) (576)
- Resistance to checkpoint blockade therapy through inactivation of antigen presentation (2017) (553)
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. (2012) (515)
- Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. (2012) (486)
- Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial (2016) (477)
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma (2014) (475)
- Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth (2015) (470)
- Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. (2016) (464)
- Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (2017) (462)
- Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. (2013) (462)
- Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases (2006) (460)
- Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. (2017) (459)
- HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. (2008) (455)
- Precision medicine for cancer with next-generation functional diagnostics (2015) (440)
- MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. (2014) (430)
- A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. (2014) (412)
- A melanocyte lineage program confers resistance to MAP kinase pathway inhibition (2013) (403)
- Toward Minimal Residual Disease-Directed Therapy in Melanoma (2018) (400)
- The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies (2015) (396)
- Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. (2013) (394)
- Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. (2007) (384)
- Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. (2018) (377)
- Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (2019) (376)
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. (2018) (372)
- Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma (2018) (356)
- Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. (2013) (346)
- From genes to drugs: targeted strategies for melanoma (2012) (346)
- Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma (2012) (327)
- Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. (2011) (327)
- Resistance to BRAF-targeted therapy in melanoma. (2013) (326)
- BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice (2012) (320)
- Mechanisms of hypertension associated with BAY 43-9006. (2006) (317)
- Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. (2007) (315)
- Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. (2017) (312)
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer (2011) (310)
- Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas (2008) (299)
- Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. (2015) (294)
- Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. (2018) (294)
- Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy (2010) (292)
- Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. (2016) (270)
- High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanoma (2018) (268)
- Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. (2007) (266)
- Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. (2016) (256)
- sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance (2016) (251)
- The MAPK pathway in melanoma (2008) (249)
- BRAF targeted therapy changes the treatment paradigm in melanoma (2011) (241)
- The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution (2020) (234)
- First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. (2017) (233)
- Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. (2016) (231)
- Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. (2017) (229)
- Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade (2014) (225)
- An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. (2007) (218)
- Elucidating distinct roles for NF1 in melanomagenesis. (2013) (212)
- Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma (2011) (209)
- Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors (2014) (209)
- CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations (2009) (204)
- Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. (2013) (202)
- Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. (2012) (202)
- Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. (2016) (195)
- Pathways and therapeutic targets in melanoma (2014) (187)
- Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma (2008) (186)
- Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). (2013) (185)
- Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. (2013) (185)
- Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. (2015) (183)
- Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy (2016) (181)
- PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance (2019) (181)
- Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. (2014) (179)
- Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. (2017) (176)
- Clinical activity of ipilimumab for metastatic uveal melanoma (2013) (176)
- Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion (2012) (172)
- Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. (2017) (172)
- Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials (2015) (169)
- Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study (2017) (169)
- Systematic identification of signaling pathways with potential to confer anticancer drug resistance (2014) (165)
- The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα. (2014) (164)
- Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. (2012) (164)
- Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma . (2012) (163)
- Melanoma: new insights and new therapies. (2012) (154)
- Chemotherapy and Targeted Therapy Combinations in Advanced Melanoma (2006) (154)
- Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). (2016) (153)
- Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. (2008) (152)
- Age as a Prognostic Factor in Patients with Localized Melanoma and Regional Metastases (2013) (150)
- Survival of patients with advanced metastatic melanoma: The impact of novel therapies. (2016) (146)
- Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma (2019) (145)
- A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel (2008) (145)
- A Prospective Study of Body Mass Index, Hypertension, and Smoking and the Risk of Renal Cell Carcinoma (United States) (2005) (144)
- BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. (2011) (142)
- Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. (2017) (141)
- Ipilimumab for patients with advanced mucosal melanoma. (2013) (140)
- Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. (2009) (137)
- Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. (2007) (137)
- Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. (2010) (135)
- Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance. (2016) (134)
- Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). (2011) (132)
- TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma (2013) (131)
- Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma. (2017) (128)
- PAK Signaling Drives Acquired Drug Resistance to MAPK Inhibitors in BRAF-mutant Melanomas (2017) (128)
- African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. (1998) (126)
- Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases (2013) (125)
- Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. (2019) (124)
- Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. (2006) (124)
- Vemurafenib Potently Induces Endoplasmic Reticulum Stress–Mediated Apoptosis in BRAFV600E Melanoma Cells (2013) (123)
- Age as a Predictor of Sentinel Node Metastasis among Patients with Localized Melanoma: An Inverse Correlation of Melanoma Mortality and Incidence of Sentinel Node Metastasis Among Young and Old Patients (2014) (122)
- Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). (2004) (119)
- Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. (2010) (119)
- BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance (2012) (117)
- Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial (2017) (117)
- Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases (2009) (115)
- The Conundrum of Genetic “Drivers” in Benign Conditions (2016) (114)
- Mutation-driven drug development in melanoma (2010) (113)
- Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. (2004) (111)
- Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. (2020) (110)
- Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC) (2005) (109)
- Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) (2020) (108)
- Tumor-associated B-cells induce tumor heterogeneity and therapy resistance (2017) (105)
- Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient Treatment (2012) (103)
- A Melanoma Molecular Disease Model (2011) (103)
- The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design (2020) (103)
- BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes (2013) (103)
- EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. (2015) (102)
- Phase I Trial of Combretastatin A-4 Phosphate with Carboplatin (2005) (101)
- Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. (2015) (101)
- Discovery and clinical introduction of first-in-class imipridone ONC201 (2016) (100)
- Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma (2016) (100)
- A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. (2017) (100)
- Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial (2019) (98)
- Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. (2008) (96)
- Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR (2015) (95)
- Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy (2018) (93)
- Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC) (2008) (91)
- Isolation and molecular characterization of circulating melanoma cells. (2014) (90)
- Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels (2007) (90)
- Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. (2010) (90)
- Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. (2018) (89)
- Integrating BRAF/MEK inhibitors into combination therapy for melanoma (2009) (86)
- BRAF, a target in melanoma (2010) (86)
- Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5−/− mice (2019) (85)
- BRAF in Melanoma: Current Strategies and Future Directions (2013) (83)
- HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. (2007) (82)
- Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). (2006) (82)
- Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings. (2017) (81)
- Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors (2011) (81)
- New Challenges in Endpoints for Drug Development in Advanced Melanoma (2011) (80)
- Biology of advanced uveal melanoma and next steps for clinical therapeutics (2014) (79)
- The state of melanoma: challenges and opportunities (2016) (79)
- Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. (2015) (79)
- Wnt5A promotes an adaptive, senescent‐like stress response, while continuing to drive invasion in melanoma cells (2015) (76)
- BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804). (2015) (76)
- BRAF inhibition generates a host/tumor niche that mediates therapeutic escape (2015) (75)
- p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. (2012) (75)
- Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. (2015) (75)
- Cutaneous effects of BRAF inhibitor therapy: a case series. (2013) (75)
- Universes collide: combining immunotherapy with targeted therapy for cancer. (2014) (75)
- Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. (2019) (75)
- A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations (2019) (74)
- Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. (2008) (74)
- Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. (2017) (74)
- Targeting the RAS pathway in melanoma. (2012) (72)
- Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells (2015) (72)
- MITF Modulates Therapeutic Resistance through EGFR Signaling (2015) (72)
- Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. (2015) (72)
- Targeting metastatic melanoma. (2012) (72)
- Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3 (2015) (70)
- Erratum: Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma (Cell (2018) 175(4) (998–1013.e20), (S0092867418313941) (10.1016/j.cell.2018.10.038)) (2019) (70)
- Sorafenib: delivering a targeted drug to the right targets (2007) (70)
- Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. (2016) (69)
- A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer. (2013) (69)
- Genetic alterations and personalized medicine in melanoma: progress and future prospects. (2014) (69)
- The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. (2011) (68)
- Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. (2020) (68)
- Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. (2020) (68)
- Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma. (2010) (67)
- Pseudoprogression in cancer immunotherapy: Rates, time course and patient outcomes. (2016) (66)
- Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. (2015) (66)
- Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. (2009) (65)
- Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation. (2019) (65)
- Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma (2018) (65)
- COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma (2014) (64)
- An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition (2017) (64)
- Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma (2016) (63)
- Considerations for the successful co-development of targeted cancer therapies and companion diagnostics (2013) (63)
- Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. (2020) (63)
- HIF- α effects on c-Myc distinguish two subtypes of sporadic VHL -deficient clear cell renal carcinoma (2009) (63)
- The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will Be (2013) (61)
- CCR Drug Updates: Sorafenib and Sunitinib in Renal Cell Carcinoma (2007) (61)
- Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights (2012) (61)
- Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600–Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials (2018) (60)
- Antisense therapeutics: lessons from early clinical trials (2001) (60)
- Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i (2020) (59)
- Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy. (2015) (59)
- Reversal of pre-existing NGFR-driven tumor and immune therapy resistance (2020) (59)
- Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells (2017) (59)
- PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo (2016) (59)
- Updated results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma (2006) (59)
- Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways (2019) (58)
- PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation (2014) (58)
- CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma (2013) (58)
- A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors (2019) (58)
- Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure (2017) (57)
- Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. (2014) (57)
- Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma. (2012) (57)
- Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival. (2016) (57)
- LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial (2020) (57)
- Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma. (2013) (56)
- Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer. (2016) (55)
- Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation (2015) (55)
- Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. (2019) (55)
- Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors (2017) (55)
- The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling (2013) (54)
- Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. (2020) (54)
- Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma (2016) (53)
- Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43–9006 alone in patients with metastatic melanoma (2005) (52)
- Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma (2019) (51)
- Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. (2017) (51)
- One Hippo and many masters: differential regulation of the Hippo pathway in cancer. (2014) (51)
- Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: A phase I subset analysis. (2006) (51)
- MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant Melanomas. (2019) (50)
- A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. (2007) (50)
- Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics (2014) (50)
- BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance (2011) (50)
- ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. (2019) (50)
- Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma. (2011) (50)
- Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase 3 IMspire170 study. (2020) (49)
- A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (Pts). (2006) (49)
- Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial. (2015) (48)
- Changes in Aged Fibroblast Lipid Metabolism Induce Age-dependent Melanoma Cell Resistance to Targeted Therapy Via the Fatty Acid Transporter FATP2. (2020) (48)
- Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. (2019) (48)
- Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM). (2011) (47)
- Allelic variation in class I HLA determines CD8+ T cell repertoire shape and cross-reactive memory responses to SARS-CoV-2 (2021) (46)
- Abstract CT232: Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer (2014) (46)
- Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors. (2013) (46)
- Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial (2011) (46)
- Distinct histone modifications denote early stress-induced drug tolerance in cancer (2017) (45)
- Targeted molecular therapy in melanoma. (2010) (45)
- Gauging the Long-Term Benefits of Ipilimumab in Melanoma. (2015) (44)
- A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States (2014) (44)
- Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805 (2015) (42)
- Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. (2012) (42)
- Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor‐targeted therapy (2012) (42)
- Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study (2011) (42)
- Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (2019) (42)
- Treatment of growing teratoma syndrome. (2009) (42)
- LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer. (2014) (41)
- Narrative Review: BRAF Opens the Door for Therapeutic Advances in Melanoma (2010) (41)
- Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma. (2014) (41)
- Collapse of the CD27+ B-Cell Compartment Associated with Systemic Plasmacytosis in Patients with Advanced Melanoma and Other Cancers (2009) (41)
- Results of COLUMBUS Part 2: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus ENCO in BRAF - Mutant Melanoma (2017) (41)
- New Strategies in Metastatic Melanoma: Oncogene-Defined Taxonomy Leads to Therapeutic Advances (2011) (40)
- Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib (2009) (40)
- [Breast cancer in the early stage]. (2012) (39)
- Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference (2007) (39)
- Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation-positive metastatic melanoma patients (pts). (2011) (39)
- Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma (2022) (39)
- Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma (2015) (39)
- Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies (2019) (38)
- Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib. (2012) (38)
- Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppresses Melanoma Viability and Tumor Growth (2013) (38)
- Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. (2021) (38)
- Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses (2021) (37)
- A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer (2019) (37)
- Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma. (2016) (37)
- Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma. (2019) (37)
- Evolution of delayed resistance to immunotherapy in a melanoma responder (2021) (37)
- PDL1 expression in desmoplastic melanoma is associated with tumor aggressiveness and progression (2017) (36)
- Immunotherapy: Anti-PD-1 therapies—a new first-line option in advanced melanoma (2015) (36)
- MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB (2016) (36)
- Effect of BRAFV600E on response to sorafenib in advanced thyroid cancer patients. (2009) (35)
- Expression of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptors 1 and 2 in Melanoma (2006) (35)
- The BEST trial (E2804): A randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC). (2013) (35)
- Sorafenib in Renal Cell Carcinoma (2007) (35)
- A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers (2018) (34)
- Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment (2015) (34)
- The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity (2018) (34)
- Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma (2015) (34)
- BRAF inhibitors and melanoma. (2011) (34)
- Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition (2019) (33)
- Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib (2014) (33)
- New molecular targets in melanoma. (2004) (33)
- Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Sub-protocol Q. (2019) (33)
- Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma. (2016) (33)
- Results from molecular analysis for therapy choice (MATCH) arm I: Taselisib for PIK3CA-mutated tumors. (2018) (33)
- Combined Effects of Yttrium-90 Transarterial Radioembolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series. (2018) (32)
- The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I. (2019) (32)
- Biological challenges of BRAF inhibitor therapy (2011) (32)
- Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab‐Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results (2017) (31)
- Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial. (2020) (31)
- Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma (2011) (31)
- Meeting report: The future of preclinical mouse models in melanoma treatment is now (2013) (31)
- New Strategies in Melanoma: Entering the Era of Combinatorial Therapy (2015) (30)
- MEK and RAF inhibitors for BRAF-mutated cancers (2012) (30)
- MicroRNA‐125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway (2017) (30)
- Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma (2005) (30)
- 6BA Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032 (2009) (30)
- Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway. (2018) (30)
- Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors (2005) (29)
- BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM). (2013) (29)
- Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer. (2014) (29)
- Molecular therapeutic approaches to melanoma. (2010) (28)
- Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma (2015) (27)
- Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM). (2014) (27)
- Emerging Strategies in Systemic Therapy for the Treatment of Melanoma. (2018) (27)
- A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITFhigh/AXLlow melanoma (2018) (27)
- Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAFV600E melanoma. (2012) (27)
- Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma. (2019) (26)
- Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome (2020) (26)
- Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131) (2020) (26)
- An Active Learning Approach for Rapid Characterization of Endothelial Cells in Human Tumors (2014) (26)
- Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma (2018) (25)
- BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma (2017) (25)
- Major response to everolimus in melanoma with acquired imatinib resistance. (2012) (25)
- Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial. (2018) (25)
- Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control. (2019) (25)
- METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM). (2012) (25)
- Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer (2014) (25)
- Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma (2018) (25)
- Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer. (2017) (25)
- PLX4032, a highly selective V600EBRAF kinase inhibitor: Clinical correlation of activity with pharmacokinetic and pharmacodynamic parameters in a phase I trial. (2009) (24)
- Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy (2021) (24)
- A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma (2018) (24)
- Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers. (2015) (24)
- Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity. (2017) (23)
- Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial (2019) (23)
- Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy. (2011) (23)
- MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib. (2013) (23)
- Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma. (2018) (23)
- First‐in‐human trial of the PI3Kβ‐selective inhibitor SAR260301 in patients with advanced solid tumors (2018) (22)
- Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma. (2021) (22)
- Where are we with adjuvant therapy of stage III and IV melanoma in 2009? (2009) (22)
- It is time to include patients with brain tumors in phase I trials in oncology. (2011) (22)
- Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805 (2017) (21)
- Cyclin‐dependent kinases as therapeutic targets in melanoma (2014) (21)
- Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials. (2015) (21)
- Abstract B080: Update on the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH/EAY131) precision medicine trial (2018) (21)
- Major therapeutic developments and current challenges in advanced melanoma (2014) (21)
- Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma. (2010) (21)
- METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAFV600/k mutant advanced or metastatic melanoma (MM). (2012) (21)
- Clinical Utility of a Blood-Based BRAFV600E Mutation Assay in Melanoma (2014) (20)
- Updated overall survival (OS) results for BRF113220, a phase I-II study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V600 metastatic melanoma (MM). (2015) (20)
- Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma (2020) (20)
- FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th2011” (2012) (20)
- Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM (2019) (20)
- NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial: A novel public-private partnership (2016) (20)
- Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion. (2020) (19)
- MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603 (2015) (19)
- Targeted therapy for metastatic melanoma. (2007) (19)
- Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma. (2014) (19)
- Innovations and Challenges in Melanoma: Summary Statement from the First Cambridge Conference (2006) (19)
- Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma. (2020) (19)
- Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment. (2009) (19)
- Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation (2019) (19)
- Genome‐wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy (2019) (19)
- Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome. (2016) (18)
- Sorafenib-Related Hand-Foot Skin Reaction Improves, Not Worsens, with Continued Treatment (2009) (18)
- The E3 ligase APC/CCdh1 promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growth (2015) (18)
- Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7 th2010" (2011) (18)
- AACR Cancer Progress Report 2017: Harnessing Research Discoveries to Save Lives (2017) (18)
- The State of Melanoma: Emergent Challenges and Opportunities (2021) (18)
- A phase II trial of gefitinib in combination with 5-FU/LV/irinotecan in patients with colorectal cancer. (2004) (18)
- Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results (2014) (18)
- Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors. (2015) (18)
- A first‐in‐human phase I, multicenter, open‐label, dose‐escalation study of the oral RAF/VEGFR‐2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status (2017) (17)
- Tissue-Agnostic Drug Development. (2017) (17)
- Preliminary results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. (2006) (17)
- Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma. (2011) (17)
- Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect (2020) (17)
- PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial. (2010) (17)
- Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma. (2021) (17)
- Pharmacodynamic study of the raf kinase inhibitor BAY 43-9006: Mechanisms of hypertension. (2004) (17)
- Phase I study of GW572016 (lapatinib), a dual kinase inhibitor, in combination with irinotecan (IR), 5-fluorouracil (FU) and leucovorin (LV) (2005) (17)
- Meeting report from the 2011 international melanoma congress, Tampa, Florida (2012) (16)
- When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age (2018) (16)
- Abstract CT101: NCI-molecular analysis for therapy choice (NCI-MATCH) clinical trial: interim analysis (2016) (16)
- Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets (2012) (16)
- Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities (2016) (16)
- Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case series. (2015) (16)
- FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology. (2019) (16)
- SARS-CoV-2 epitope-specific CD4+ memory T cell responses across COVID-19 disease severity and antibody durability (2022) (16)
- Local Recurrence Following Resection of Intermediate-High Risk Non-metastatic Renal Cell Carcinoma: An Anatomic Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial. (2020) (15)
- An Open-Label, Dose–Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma (2016) (14)
- Biomarkers in Melanoma: Lessons from Translational Medicine. (2016) (14)
- A phase II study of imatinib for advanced melanoma patients with KIT aberrations. (2010) (14)
- Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors (2021) (14)
- Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma (2021) (14)
- AB065. P-36. Debio 1347 in patients with cholangiocarcinoma harboring an FGFR gene alteration: preliminary results (2019) (14)
- A phase II trial of perifosine in patients with advanced renal cell carcinoma (RCC) who have failed tyrosine kinase inhibitors (TKI). (2009) (14)
- Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors (2015) (13)
- Abstract PR06: Phase 1b dose-escalation study of trametinib (MEKi) plus palbociclib (CDK4/6i) in patients with advanced solid tumors (2015) (13)
- Early FDG-PET responses to PLX4032 in BRAF-mutant advanced melanoma. (2010) (13)
- Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours (2019) (13)
- A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine (2004) (13)
- Is it good or bad to find a BRAF mutation? (2011) (13)
- Modifying phase I methodology to facilitate enrolment of molecularly selected patients. (2013) (13)
- Melanoma and immunotherapy bridge 2015 (2016) (13)
- Abstract P5-19-13: Clinical activity of abemaciclib, an oral cell cycle inhibitor, in metastatic breast cancer (2015) (13)
- Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors. (2017) (13)
- First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study. (2017) (13)
- Abstract 958: Treatment with a selective inhibitor of BRAFV600E increases melanocyte antigen expression and CD8 T cell infiltrate in tumors of patients with metastatic melanoma (2011) (13)
- Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT). (2013) (12)
- Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma (2019) (12)
- PI 3 K pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo (2017) (12)
- Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma (2018) (12)
- VEGF, VEGFR1, and VEGFR2 expression in melanoma (2007) (12)
- Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. (2019) (12)
- Phase I Study of Weekly Liposome-Encapsulated Doxorubicin in Patients With Advanced, Androgen-Independent Prostate Cancer (2004) (12)
- Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma (2021) (12)
- NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with untreated or progressed after first-line immunotherapy unresectable or metastatic NRAS-mutant cutaneous melanoma. (2014) (11)
- Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients. (2015) (11)
- The future of tyrosine kinase inhibitors: Single agent or combination? (2008) (11)
- Abstract LB-350: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition by vemurafenib (2012) (11)
- NCI-MATCH (Molecular Analysis for Therapy Choice) – a national signal finding trial. (2016) (11)
- Selective uveal melanoma inhibition with calcium channel blockade (2019) (11)
- Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC). (2009) (11)
- Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H. (2019) (11)
- Preclinical and clinical development of targeted therapy in melanoma: attention to schedule (2009) (11)
- HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors (2022) (11)
- Unusual hematologic malignancies. Case 1. Hematologic malignancy presenting with diarrhea and bony lesions: systemic mastocytosis. (2002) (11)
- Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death and abrogates invasive growth of melanoma cells (2008) (11)
- Melanoma in 2017: Moving treatments earlier to move further forwards (2018) (11)
- NCI-MATCH Arms N & P: Phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss. (2018) (10)
- Safety and efficacy of the selective FGFR inhibitor debio 1347 in phase I study patients with FGFR genomically activated advanced biliary tract cancer (BTC). (2018) (10)
- Drug targeting of oncogenic pathways in melanoma. (2009) (10)
- Advances in drug development. BRAF validation in melanoma. (2010) (10)
- Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective. (2021) (10)
- YAP in MAPK pathway targeted therapy resistance (2015) (10)
- SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth (2020) (10)
- 1244PHospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma (2017) (10)
- STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming (2022) (10)
- Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study. (2017) (10)
- 1130TiPNEMO: A PHASE 3 TRIAL OF BINIMETINIB (MEK162) VERSUS DACARBAZINE IN PATIENTS WITH ADVANCED NRAS-MUTANT MELANOMA WHO ARE UNTREATED OR HAVE PROGRESSED AFTER ANY NUMBER OF IMMUNOTHERAPY REGIMENS. (2014) (9)
- Her-2 targeted therapy: Beyond breast cancer and trastuzumab (2006) (9)
- Expanded access programmes: patient interests versus clinical trial integrity. (2015) (9)
- A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma. (2013) (9)
- Assessment of PI3 kinase as a druggable target in melanoma (2007) (9)
- Vemurafenib: B-raf kinase inhibitor, oncolytic (2011) (9)
- Cardiac safety analysis for a phase III trial of sunitinib (SU) or sorafenib (SO) or placebo (PLC) in patients (pts) with resected renal cell carcinoma (RCC). (2012) (9)
- First use of an oral Hsp90 inhibitor in patients (Pts) with solid tumors: Alvespimycin (A) administered QOD or Q (2008) (9)
- Tracking early response to immunotherapy (2020) (9)
- Overall survival and biomarker analysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma. (2020) (9)
- Efficacy of vemurafenib in BRAFV600K mutation positive melanoma disease - results from the phase III clinical study BRIM-3. (2011) (9)
- Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E mutated melanoma: an update from the phase III randomized, open-label, multicenter BRIM3 trial (2011) (9)
- COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma (2022) (9)
- Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T). (2013) (8)
- Effect of the farnesyl transferase inhibitor lonafarnib on sensitivity of melanoma cells to the multikinase inhibitor sorafenib and on Rheb farnesylation and mTOR signaling. (2016) (8)
- Plasma-based monitoring of BRAF mutations during therapy for malignant melanoma (MM) using combined exosomal RNA and cell-free DNA analysis. (2015) (8)
- Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas (2018) (8)
- Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era (2015) (8)
- Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. (2021) (8)
- Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer. (2015) (8)
- The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial. (2020) (8)
- Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase I Study. (2021) (8)
- Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma (MM). (2017) (8)
- COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant (mut) melanoma brain metastases (MBM). (2017) (8)
- Next generation therapies change the landscape in melanoma (2011) (8)
- Throwing the kitchen sink at melanoma drug development (2012) (8)
- A first-in-human dose phase 1 study of LY3009120 in advanced cancer patients. (2017) (8)
- Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial (2022) (8)
- Abstract CT139: NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations (2019) (8)
- First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737). (2015) (8)
- A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma. (2015) (8)
- Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis (2022) (8)
- Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance (2019) (8)
- Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma (2015) (8)
- Loss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF inhibition. (2020) (7)
- Using benchmarks based on historical survival rates for screening new therapies for stage IV melanoma patients. (2008) (7)
- Tissue-Agnostic Drug Development. (2017) (7)
- High-Throughput Testing of Novel-Novel Combination Therapies for Cancer: An Idea Whose Time Has Come. (2016) (7)
- Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research Congress (2011) (7)
- Hyperspectral imaging: A non-invasive method of imaging melanoma lesions in a patient with stage IV melanoma, being treated with a RAF inhibitor (2011) (7)
- Dose analysis of ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial. (2015) (7)
- Benefit and toxicity of programmed death‐1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study * (2022) (7)
- Anti-PD-1 antibody treatment for melanoma. (2018) (7)
- Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/Kmutation-positive cutaneous melanoma. (2015) (7)
- Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Phase 1 results. (2015) (7)
- A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors (2016) (7)
- Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance (2016) (6)
- Abstract 4282: Deconvolution of plasma-derived exosomes for tracking and prediction of immunotherapy across multiple tissues (2018) (6)
- Cutaneous effects of BRAF inhibitor therapy: a case series. (2013) (6)
- Medical oncologists’ clinical experiences and comfort levels with 20 recently approved agents. (2013) (6)
- Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. (2019) (6)
- The PI3K inhibitor BKM120 has potent antitumor activity in melanoma brain metastases in vitro and in vivo. (2013) (6)
- Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations (2017) (6)
- Immune checkpoint inhibition (ICI) in advanced cutaneous squamous cell carcinoma (cSCC): Clinical response and correlative biomarker analysis. (2018) (6)
- Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600–mutant melanoma. (2019) (6)
- Necuparanib combined with nab-paclitaxel + gemcitabine in patients with metastatic pancreatic cancer: Phase 2 results. (2017) (6)
- Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib. (2019) (6)
- A phase II study of sorafenib in metastatic thyroid carcinoma (2008) (6)
- Vemurafenlb Improves Overall Survival Compared to Dacarbazlne In Advanced BRAFV600E-mutated Melanoma: Updated Survival Results From a Phase III Randomised, Open-label, Multlcentre Trial (2011) (6)
- Society for Melanoma Research 2015 Congress (2015) (6)
- Phase I/II trial of imatinib and temozolomide in advanced unresectable melanoma (2008) (6)
- Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F (2022) (6)
- Seminar article Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma (2008) (6)
- Abstract CT138: NCI-MATCH EAY131 -Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containingBRCA1andBRCA2mutations (2019) (6)
- Pooled analysis of safety over time and link between adverse events and efficacy across combination dabrafenib and trametinib (D+T) registration trials. (2016) (6)
- Predicting early relapse in patients with BRAFV600E melanoma with a highly sensitive blood BRAF assay. (2012) (5)
- Activity of the MEK Inhibitor Trametinib (GSK1120212) in Advanced Melanoma in a Phase I, Dose-escalation Trial (2014) (5)
- Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). (2021) (5)
- Phase I trial of imatinib and temozolomide in patients with metastatic melanoma. (2004) (5)
- A phase Ib study of napabucasin plus weekly paclitaxel in patients with advanced melanoma. (2017) (5)
- Impact of gene expression profiles on clinical predictors of survival in patients (pts) with BRAFV600-mutated metastatic melanoma (mM). (2017) (5)
- Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer (2003) (5)
- Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort (2021) (5)
- Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration—Melanoma Research Alliance Public Workshop (2020) (5)
- Tumor Genomic Profiling Practices and Perceptions: A Survey of Physicians Participating in the NCI-MATCH Trial. (2020) (5)
- Rejection of benign melanocytic nevi by nevus-resident CD4+ T cells (2021) (5)
- Targeting TBK1 to overcome resistance to cancer immunotherapy (2022) (5)
- Meeting Report from the Third Global Workshop on Melanoma (2010) (5)
- Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (2020) (5)
- Final results of a phase I trial of sorafenib and bevacizumab in patients with metastatic renal cell cancer (mRCC). (2007) (5)
- Persistent corneal defect caused by Listeria monocytogenes. (1990) (5)
- Characteristics of pyrexia in BRAF V 600 E / K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I / II clinical trial (2015) (4)
- Myeloid-derived itaconate suppresses cytotoxic CD8+ T cells and promotes tumour growth. (2022) (4)
- Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib (2021) (4)
- Commentary: Molecular testing in melanoma. (2014) (4)
- Which questions remain unanswered following the successful development of sorafenib in hepatocellular carcinoma? (2009) (4)
- M402, a heparan sulfate mimetic and novel candidate for the treatment of pancreatic cancer. (2012) (4)
- Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5−/− mice (2019) (4)
- Pyrexia-related outcomes upon application of an adapted pyrexia management algorithm in patients (pts) with BRAF V600: Mutant unresectable or metastatic melanoma treated with dabrafenib plus trametinib (DabTram) in the COMBI-i trial. (2021) (4)
- Anti-tumor Activity of a Mitochondrial Targeted HSP90 Inhibitor in Gliomas. (2022) (4)
- Phase I-II study of the combination vemurafenib plus peg-interferon in advanced melanoma patients harboring the V600BRAF mutation. (2014) (4)
- New options and new questions: how to select and sequence therapies for patients with metastatic melanoma. (2012) (4)
- Image-guided biopsy in the age of personalised medicine: strategies for success and safety. (2020) (4)
- Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies (2004) (4)
- Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F. (2020) (4)
- Profiling exosomal mRNAs in patients undergoing immunotherapy for malignant melanoma. (2015) (4)
- Phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of oral alvespimycin (A; KOS-1022; 17-DMAG): Two different schedules in patients with advanced malignancies (2007) (4)
- Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors. (2022) (4)
- Whole exome and whole transcriptome sequencing in melanoma patients to identify mechanisms of resistance to combined RAF/MEK inhibition. (2013) (4)
- Prognostic subgroups and impact of treatment for post-progression overall survival (ppOS) in patients (pts) with BRAFV600-mutated metastatic melanoma treated with dacarbazine (DTIC) or vemurafenib (VEM) ± cobimetinib (COBI): A pooled analysis (2016) (4)
- Where does the combination of sorafenib and interferon in renal cell carcinoma stand? (2009) (4)
- Phase II Trials (2004) (4)
- Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials (2020) (4)
- Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I (2022) (3)
- Abstract PL03-01: NCI-MATCH: A new paradigm in the era of genomic oncology (2018) (3)
- The molecular context of vulnerability for CDK9 suppression in triple wild-type melanoma. (2021) (3)
- Corrigendum: Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma (2012) (3)
- Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. (2011) (3)
- Effect of mTOR inhibitors on sorafenib-induced endoplasmic reticulum stress and apoptosis in melanoma cells. (2010) (3)
- Abstract C139: Detection of BRAF mutations in serum/plasma microvesicles (exosomes) of malignant melanoma patients. (2011) (3)
- Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting (2019) (3)
- Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel (2013) (3)
- Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance (2021) (3)
- 1245PQuality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma (2017) (3)
- Adverse events of special interest in the phase 3 COLUMBUS study. (2018) (3)
- Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: preliminary results. (2019) (3)
- Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B. (2022) (3)
- Abstract C137: Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients. (2013) (3)
- Prognostic and predictive role of circulating angiopoietin-2 in multiple solid tumors: An analysis of approximately 500 patients treated with lenvatinib across tumor types. (2014) (3)
- Abstract LB-010: Molecular analysis for therapy choice (NCI-MATCH, EAY131) arm Z1B: Phase II trial of palbociclib forCCND1, 2 or 3amplified tumors (2019) (3)
- Hope in translation (2010) (3)
- First-in-human phase I “basket” study of Debio1347 (CH5183284), a novel FGFR inhibitor, in patients with FGFR genomically activated advanced solid tumors. (2014) (3)
- A single-arm, open-label, U.S. expanded access study of vemurafenib in patients with metastatic melanoma. (2012) (3)
- Identifying prognostic subgroups for outcomes in BRAFV600-mutated metastatic melanoma patients (pts) treated with vemurafenib (V) ± cobimetinib (C): A pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. (2016) (3)
- Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts (2018) (3)
- Response to Immune Checkpoint Antibodies: Not All Responses Are Created Equal (2018) (3)
- Design and development of the molecular analysis for Therapy Choice (NCI-MATCH) Designated Laboratory Network. (2019) (3)
- A phase I trial of RAD001 in combination with cetuximab in patients with advanced solid tumors (2007) (2)
- A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation (2021) (2)
- Autoimmune genetic variants as germline biomarkers of response in melanoma immunotherapy treatment. (2018) (2)
- Predictable early onset high-dose-glucocorticoid-associated-irAE and its predictive role in anti-PD-1 monotherapy treated advanced melanoma patients. (2019) (2)
- A phase II study of combined therapy with vemurafenib (vem) and high-dose interleukin-2 (aldesleukin; HD IL-2) in patients with metastatic melanoma. (2015) (2)
- Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials (2019) (2)
- The Impact of Timing of Immunotherapy with Cranial Irradiation on Early Distant Brain Progression and Overall Survival in Patients with Melanoma Brain Metastases (2017) (2)
- Survival patterns following brain metastases for patients with melanoma in the targeted therapy era. (2013) (2)
- The effect and mechanism of M402 on gemcitabine uptake into pancreatic tumors. (2014) (2)
- Quality-of-Life (QoL) in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma (2017) (2)
- Abstract PR03: A phase 1 trial of AG-270 in patients with advanced solid tumors or lymphoma with homozygousMTAPdeletion (2019) (2)
- Hyperspectral imaging: A noninvasive in vivo method of imaging melanoma lesions in a patient being treated with a novel B-RAF inhibitor. (2010) (2)
- Preliminary evaluation of response to combination of RAD001 and cetuximab using [18F]-fluorodeoxyglucose positron emission tomography (18FDG-PET) (2008) (2)
- Abstract PR10: A cyclic AMP-regulated melanocyte lineage program confers resistance to MAP kinase pathway inhibition (2013) (2)
- Heterogeneous response and irAE patterns in advanced melanoma patients treated with anti-PD-1 monotherapy from different ethnic groups: Subtype distribution discrepancy and beyond. (2020) (2)
- PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K–mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study. (2017) (2)
- Abstract LB-B30: First in human, dose escalation trial of the combination of dabrafenib, trametinib, and navitoclax in patients with BRAF mutant solid tumors (2018) (2)
- A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG‐ACRIN Cancer Research Group (EAQ152) (2021) (2)
- Meeting report: consensus from the first and second Global Workshops in Melanoma November 19–20, 2008 (2009) (2)
- Abstract 4568: Rapid assessment of TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF mutant melanoma. (2013) (2)
- Collapse of the CD 27 + B-Cell Compartment Associated with Systemic Plasmacytosis in Patients with Advanced Melanoma and Other Cancers (2009) (2)
- Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma. (2015) (2)
- Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma. (2020) (2)
- Analysis of serum biomarkers and tumor genetic alterations from a phase II study of lenvatinib in patients with advanced BRAF wild-type melanoma. (2013) (2)
- Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i) (2022) (2)
- Association of plasma exosomal mRNA changes with long-term durable response to ipilimumab (IPI) in metastatic melanoma (MM) patients. (2016) (2)
- Meeting report from the “ Melanoma Research : a bridge from Naples to the World . Napoli , December 5 th – 6 th 2011 ” (2012) (2)
- Characterization of immune related hepatitis (irH) from immune checkpoint inhibitors (ICIs). (2018) (2)
- Abstract A35: BRAF inhibition increases exosomal PD-L1 protein expression in melanoma (2018) (2)
- Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805) (2021) (2)
- Plasma-derived exosomal analysis and deconvolution enables prediction and tracking of melanoma checkpoint blockade response (2019) (2)
- Targeting signal transduction pathways in melanoma (2010) (2)
- Efficacy, safety, and pharmacokinetics (PK) of the BRAF inhibitor dabrafenib (D) hydroxypropyl methylcellulose (HPMC) capsule formulation in combination with the MEK1/2 inhibitor trametinib (T) in patients (pts) with BRAF mutation-positive metastatic melanoma (MM). (2013) (2)
- Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib (2012) (2)
- 454 Monitoring therapy response and resistance mutations in circulating RNA and DNA of plasma from patients with malignant melanoma (2014) (2)
- Induction of apoptosis by the BRAFV600E kinase inhibitor PLX4032 in BRAFV600E melanoma cells through regulation of endoplasmic reticulum stress-related genes. (2011) (2)
- Proteasomal down-regulation of the proapoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanoma (2022) (2)
- In the pipeline: encorafenib and binimetinib in BRAF-mutated melanoma. (2017) (2)
- The use of Anti-PD1 Therapy in Melanoma Patients with Known Brain Metastases: Survival, Durable Intracranial Progression Free Survival and Radionecrosis (2018) (2)
- Abstract 2338: BRAF inhibition is associated with increased clonality of tumor infiltrating lymphocytes. (2013) (2)
- 1041MO 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma (2021) (2)
- Palliative care and hospice use among melanoma patients treated with immunotherapy. (2015) (2)
- Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial. (2022) (2)
- Abstract 4533: Plasma and exosome proteomic profiling for prediction of immunotherapy response and toxicity (2019) (2)
- A phase I study of the combination of sorafenib (Sor) and bortezomib (Bor) in patients (pts) with metastatic melanoma (MM). (2013) (1)
- NEMO: A Phase 3 Trial of Binimetinib (MEK162) Versus Dacarbazine in Patients With Advanced NRAS-Mutant Melanoma Who Are Untreated or Have Progressed After Immunotherapy (2014) (1)
- 23 Clinical Status of RAF/MEK Inhibitors (2012) (1)
- Liquid biopsy using plasma proteomic profiling to reveal predictors of immunotherapy response. (2019) (1)
- Abstract 5557: Mutation analysis of melanoma tumor samples from ECOG 2603 clinical trial (2012) (1)
- AACR Calls on Congress to Take Immediate Action Against COVID-19 and Protect Patients with Cancer During the Pandemic. (2020) (1)
- Inflammatory arthritis: An under-recognized immune-relate adverse effect. (2017) (1)
- 553P Activity of trastuzumab and pertuzumab (HP) in patients with non-breast/gastroesophgeal HER2-amplified tumours: Results of the NCI-MATCH trial (EAY131) subprotocol J (2020) (1)
- Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM (2019) (1)
- Plasma proteomic biomarkers identify non-responders and reveal biological insights about the tumor microenvironment in melanoma patients after PD1 blockade (2022) (1)
- Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results (2014) (1)
- Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q' (2021) (1)
- When are signal transduction targeted therapies acting as immunotherapy? (2015) (1)
- Dose reductions and delays in patients (pts) with renal cell carcinoma (RCC) treated with sorafenib (SR) or sunitinib (SU): Retrospective analysis of two large U.S. health care claims databases. (2010) (1)
- A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas (2021) (1)
- Abstract 1610: MAPK inhibitor resistance leads to ligand-independent Ephrin A2 receptor signaling and the formation of new melanoma metastases (2014) (1)
- The use of plasma proteomic markers to understand the biology of immunotherapy response. (2020) (1)
- Abstract A053: Prevalence of mismatch repair deficiency (dMMR) in the NCI Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) population (2018) (1)
- Academic Cancer Center Phase I Program Development (2017) (1)
- Tumor-associated B-cells induce tumor heterogeneity and therapy resistance (2017) (1)
- 871P Predictive role of neutrophil-lymphocyte ratio (NLR) in patients (pts) with metastatic melanoma: A post hoc exploratory analysis from phase III COMBI-i trial (2022) (1)
- Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy (2003) (1)
- Circulating tumor DNA (ctDNA) kinetics to predict survival in patients (pts) with unresectable or metastatic melanoma treated with dabrafenib (D) or D + trametinib (T). (2019) (1)
- Abstract 4837: Tumor microenvironment contributes to RAF-inhibitor resistance through HGF secretion (2012) (1)
- Abstract 4017: Anti-tumor activity of a BRAF inhibitor and IFNα combination in BRAF mutant melanoma (2016) (1)
- Abstract B16: NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with advanced NRAS-mutant melanoma who are untreated or have progressed on or after immunotherapy (2015) (1)
- Targeting BRAF Activity as a Novel Paradigm for Melanoma Therapy (2008) (1)
- Health-related quality-of-life (HRQOL) impact of dabrafenib (D) and trametinib (T) vs BRAF inhibitor (BRAFi) monotherapy by lactate dehydrogenase (LDH) in patients (pts) with BRAF V600–mutant melanoma (2016) (1)
- National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) (2023) (1)
- Germany rising (2010) (1)
- Abstract LB-239: The Hippo effector YAP promotes resistance to RAF and MEK targeted therapies (2015) (1)
- Scratching the combinatorial drug landscape surface (2013) (1)
- ASN003, a highly selective BRAF and PI3K inhibitor: Preclinical and phase 1 clinical data in patients with advanced solid tumors. (2017) (1)
- Supplemental Data Reduction of TRAIL-Induced Mcl-1 and cIAP 2 by c-Myc or Sorafenib Sensitizes Resistant Human Cancer Cells to TRAIL-Induced Death (2007) (1)
- Somatic genetics and targeted therapies for cutaneous melanoma (2008) (1)
- Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T). (2019) (1)
- Increase in blood pressure with sorafenib exposure in renal cell carcinoma versus other solid tumors. (2013) (1)
- Cancer Management Chapter 20: Melanoma and other skin cancers (2010) (1)
- Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy (2018) (1)
- A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U. (2021) (1)
- The impact of obesity on outcomes in metastatic melanoma (MM) patients (pts) treated with dabrafenib and trametinib. (2016) (1)
- The Clinical Development of Lurtotecan (2005) (1)
- A multivariate analysis of prognostic factors from assure (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma. (2016) (1)
- Abstract 1970: Inhibition of BRAF-V600E increases melanocyte antigen expression and antigen-specific recognition in melanoma without altering T cell function (2010) (1)
- Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha (2022) (1)
- Abstract A079: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH): A successful precision medicine signal-seeking trial in patients (pts) with rare variants and refractory malignancies (2019) (1)
- Abstract LBA003: Erdafitinib in patients with tumors harboring FGFR gene mutations or fusions: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol K2 (2021) (1)
- 819P Efficacy of dabrafenib (D) trametinib (T) plus spartalizumab (S) by baseline site of metastases in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Post hoc analysis of phase III COMBI-i trial (2022) (1)
- Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study (2022) (1)
- Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1K (2022) (1)
- Characteristics of Patients With a Complete Response Treated With Dabrafenib + Trametinib Combination Therapy: Findings From Pooled COMBI-d and COMBI-v 5-Year Analysis (2020) (1)
- Is ERK activation a good biomarker for estradiol and tamoxifen effects? (2007) (1)
- Oncogenic KIT Induces Replication stress and Confers Cell Cycle Checkpoint Vulnerability in Melanoma. (2021) (1)
- Abstract PR04: A melanoma transcriptional state distinction influences sensitivity to MAPK pathway inhibitors (2015) (1)
- Axitinib in Combination with Toripalimab, a Humanized IgG4 mAb Against Programmed Death-1 (PD-1) in Patients with Metastatic Mucosal Melanoma: A Non-Randomized, Open-Label, Dose-Finding, and Cohort-Expansion Phase 1b Trial (2019) (1)
- PCN110 A RETROSPECTIVE CLAIMS DATABASE COMPARISON OF SORAFENIB AND SUNITINIB DOSING PATTERNS IN PATIENTS WITH RENAL CELL CARCINOMA (RCC) (2009) (1)
- Targeted Inhibition of B-Raf (2012) (1)
- Tumor-specific circulating cell-free DNA (cfDNA) to predict clinical outcome in BRAF V600 mutation-positive melanoma patients (pts) treated with the MEK inhibitor trametinib (T) or chemotherapy (C). (2013) (1)
- 150 Circulatory plasma proteomic biomarkers predict response to immunotherapy in melanoma patients and reveal biological insights into the tumor microenvironment (2022) (1)
- Discrepancies in response and immune-related adverse events (irAE) of anti-PD-1 monotherapy between races and primary sites in patients (pts) with advanced nonacral cutaneous melanoma (NACM). (2021) (1)
- Single-cell RNA-sequencing and -imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockade. (2018) (1)
- Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma (2018) (0)
- Abstract A089: Adolescent and young adult (AYA) cohort of the NCI MATCH clinical trial (EAY131) (2019) (0)
- Abstract 296: Targeting the melanosome: overcoming MAPK-inhibitor resistance in melanoma (2016) (0)
- Effectively targeting CRAF: rational serendipity targeting SRC? (2015) (0)
- Abstract 62: Destabilization ofNOXAmRNA as a common resistance mechanism to targeted therapies (2020) (0)
- Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A (2022) (0)
- 1259TiPA randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600–mutant melanoma (COMBI-i) (2017) (0)
- Response toBRAF Inhibition inMelanoma Is EnhancedWhen Combined with Immune Checkpoint Blockade (2014) (0)
- Faculty Opinions recommendation of Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. (2007) (0)
- Abstract 2841: A co-clinical assessment of patterns of BRAF inhibitor resistance (2015) (0)
- Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review. (2013) (0)
- Principles of Targeted Therapy (2019) (0)
- 128 INVITED Melanoma Therapy – Realising the Potential in Targeted Therapy (2011) (0)
- Abstract PR8: Insensitivity to RAF inhibition by vemurafenib in BRAF mutant colorectal cancer by EGFR-mediated reactivation of MAPK signaling (2012) (0)
- New Approaches to Signaling (2017) (0)
- Proffered Paper: Utilising non-mutational drug-tolerance prolongs and improves targeted melanoma therapy (2016) (0)
- Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas (2018) (0)
- Data-driven discovery of targets for bipotent anticancer drugs identifies Estrogen Related Receptor Alpha (2021) (0)
- Background M402, a Novel Drug Candidate for Pancreatic Cancer: Efficacy in Animal Models and Initial Clinical Study Design (2014) (0)
- Detection of low abundant somatic mutations in circulating exosomal RNA and cfDNA with next-generation sequencing. (2015) (0)
- Investigating the tumor immune infiltrate for populations that predict immune-related adverse events (irAEs) in patients receiving PD-1 inhibitors. (2020) (0)
- Abstract 3013: Acquired resistance to immune checkpoint inhibition by melanoma phenotypic transformation (2019) (0)
- Angiogenic factor and cytokine analysis among patients with renal cell carcinoma treated with adjuvant VEGFR TKIs. (2019) (0)
- A phase II, open-label, randomized, multicenter trial of encorafenib + binimetinib evaluating a standard-dose and a high-dose regimen in patients with BRAFV600-mutant melanoma brain metastasis (MBM) (POLARIS) (2019) (0)
- 462 Clinical Utility of a Highly Sensitive Blood BRAF Assay in Patients with Stage II and III Malignant Melanoma (2012) (0)
- Title: Pharmacology, Feedback, and Novel Agents in the MAP Kinase Pathway (2014) (0)
- The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. (2022) (0)
- Abstract 6403: Molecular correlates of clinical benefit from circulating tumor DNA (ctDNA): Analysis of the COLUMBUS study (2022) (0)
- Targeted Therapies for BRAF-Mutant Metastatic Melanoma (2018) (0)
- 314 Optimal sequencing schedules for combining BRAF inhibition with BCL-2 inhibition (2014) (0)
- Functional characterization of non-V600 BRAF mutations and their response to Trametinib (Tram). (2016) (0)
- Dosing patterns in patients with renal cell carcinoma treated with sorafenib or sunitinib: A retrospective claims database analysis. (2009) (0)
- Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRAS-mutant melanoma cells to the MEK inhibitor binimetinib. (2014) (0)
- Apoptosis in BRAFV600E Melanoma Cells Vemurafenib Potently Induces Endoplasmic Reticulum Stress-Mediated ` (2013) (0)
- New signal transduction inhibitors (2012) (0)
- Validation in Melanoma (2013) (0)
- Abstract 6670: Combined signals from tumor and immune cells predict outcomes of checkpoint inhibition in melanoma (2020) (0)
- Abstract CN07-01: Monitoring downstream responses to MAP kinase pathway inhibitor therapy in BRAF mutant melanoma to support rational combinations strategies. (2013) (0)
- Abstract B25: Exosomal transcriptomic signatures tracks and predicts response to checkpoint blockade immunotherapy (2018) (0)
- ONC201, a small molecule Foxo3a activator, activity against patient-derived glioblastoma tumor-initiating cells. (2014) (0)
- Abstract 4668: Targeted, massively parallel sequencing identifies novel genetic subsets of cutaneous melanoma (2015) (0)
- Abstract B17: Identification of drugs that synergize with immunotherapies (2020) (0)
- Moving Forward: Making BRAF-Targeted Therapy Better (2015) (0)
- Abstract B25: Demographic characteristics and peripheral blood clinical laboratory variables predict irAE occurrence in patients with advanced melanoma receiving anti-PD-1 monotherapy (2020) (0)
- Abstract PR06: A co-clinical assessment of patterns of BRAF inhibitor resistance (2015) (0)
- The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. (2022) (0)
- The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. (2022) (0)
- The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. (2022) (0)
- 916 Acquired resistance to immune checkpoint blockade by phenotypic plasticity of melanoma (2022) (0)
- BMET-04LEPTOMENINGEAL CARCINOMATOSIS IN MELANOMA (2015) (0)
- Association of the activation of the mTOR pathway with prognosis in Chinese melanoma patients. (2012) (0)
- How to Overcome Resistance in Mutation Driven Therapies Combination Targeted Therapy Regimens (2012) (0)
- Abstract 5833: Escape form adaptive drug tolerance through OGT and TET1 mediated H3K4me3 remodeling in MAPKi resistant melanoma (2018) (0)
- Combination therapy for renal cell carcinoma: review of the clinical evidence (2011) (0)
- Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group‐American College of Radiology Imaging Network (ECOG‐ACRIN) E2805 (2021) (0)
- New Therapeutic Approaches in Signaling (2011) (0)
- New drugs in development for melanoma. (2015) (0)
- 1241PImpact of duration of response (DOR) on overall survival (OS) in patients with metastatic melanoma treated with dacarbazine (DTIC), vemurafenib (V), or cobimetinib plus vemurafenib (C+V): a pooled analysis (2017) (0)
- Phase II study of sunitinib in tumors with c-KIT mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol V (2022) (0)
- The melanoma metastasis X‐factor (2014) (0)
- Extreme Vulnerability of ID H 1 Mutant Cancers to NAD + Depletion Graphical Abstract Highlights (0)
- Evaluation of response to sorafenib in metastatic thyroid cancer with FDG PET (2008) (0)
- Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. (2012) (0)
- A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation (2021) (0)
- CMET-33. PHASE II STUDY OF PALBOCICLIB IN BRAIN METASTASES HARBORING CDK PATHWAY ALTERATIONS (2019) (0)
- Abstract CT061: Binimetinib in patients with tumors withNRASmutations: NCI-MATCH ECOG-ACRIN Cancer Research Group subprotocol EAY131-Z1A (2020) (0)
- Phylogenetic analysis of longitudinal melanoma samples to reveal convergent evolution and markers of immunotherapy resistance. (2018) (0)
- Companion Diagnostics and Cancer Biomarkers Clinical Utility of a Blood-Based BRAFV 600 EMutation Assay in Melanoma (2014) (0)
- 530P Phase II study of PI3K inhibitor copanlisib in cancer patients with deleterious PTEN mutations and retained PTEN protein expression: Results from the NCI-MATCH Trial (EAY131) sub-protocol Z1H (2021) (0)
- MP14-18 AN ANATOMIC CLASSIFICATION SYSTEM FOR LOCAL RECURRENCE FOLLOWING RESECTION OF INTERMEDIATE AND HIGH RISK NON-METASTATIC RENAL CELL CARCINOMA: AN ANALYSIS OF THE ASSURE (ECOG-ACRIN 2805) TRIAL (2019) (0)
- Abstract B118: A phase 1, open-label multiple dose escalation trial to determine safety and tolerability of once daily OPB-111077 in subjects with advanced cancer (2015) (0)
- Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (2020) (0)
- Abstract B147: A phase 1 PK/PD study of ASN003, a novel, highly selective BRAF and PI3K dual inhibitor, in patients with advanced solid tumors (2018) (0)
- Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (2019) (0)
- Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance (2023) (0)
- Faculty Opinions recommendation of BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. (2012) (0)
- Abstract 5237: Systems level modeling following BRAF inhibition reveals an essential role for Ephrin A2 receptor in therapeutic escape. (2013) (0)
- Abstract CT003: Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients withBRAFandNRASmutant melanoma (2017) (0)
- Melanoma and immunotherapy bridge 2015 (2016) (0)
- Abstracts of Melanoma 2010 Congress, the 7th International Melanoma Research Congress and the 4th Melanoma & Skin Cancer Centres Meeting. November 4-7, 2010. Sydney, Australia. (2010) (0)
- The development of the BRAF inhibitor encorafenib (LGX818) and mitogen-activated protein kinase kinase inhibitor binimetinib (MEK162) in patients with metastatic melanoma (2014) (0)
- A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation (2021) (0)
- 452 Profiling exosomal mRNAs in patients undergoing immunotherapy for malignant melanoma (2015) (0)
- 484 Treatment of advanced solid tumors with golvatinib (E7050) in combination with lenvatinib (E7080) (2014) (0)
- Abstract IA05: Selective pressure by activated T cells identifies de novo and adaptive resistance mechanisms in melanoma (2018) (0)
- Prognostic models for advanced melanoma patients treated with anti-PD-1 monotherapy. (2019) (0)
- Abstract PR18: Comparative screening of skin-derived NCSCs, melanocytes, and melanoma developmental programs reveals LPAR1 in MAPKi resistance (2020) (0)
- Review Genetic Alterations and Personalized Medicine in Melanoma (2014) (0)
- Phase II Three-Arm Randomised Study of the Braf Inhibitor (BRAFI) Dabrafenib Alone vs Combination with Mek1/2 Inhibitor (MEKI) Trametinib in Pts with Braf V600 Mutation-Positive Metastatic Melanoma (MM) (2012) (0)
- Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). (2011) (0)
- Melanoma therapy: from frustration to enthusiasm (2012) (0)
- Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B (2023) (0)
- 1237 Escape form adaptive drug tolerance through OGT and TET1 mediated H3K4me3 remodeling in MAPKi-resistant melanoma (2018) (0)
- Abstract CT019: ASN003, a novel highly selective BRAF and PI3K dual inhibitor: Phase I PK/PD results in patients with advanced solid tumors (2018) (0)
- When the nurse becomes the patient. (1997) (0)
- Expression quantitative trait loci (eQTLs) as germline determinants of melanoma immunotherapy response. (2017) (0)
- Imaging with [18f]-fluorodeoxyglucose positron emission tomography (FDG-PET) and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) as markers of drug effect in a phase I dose-escalation study of combined RAD 001 and cetuximab. (2011) (0)
- 1127P Correlation of BRAF mutation status in circulating tumour DNA (ctDNA) with tumour biopsy and clinical outcomes in COLUMBUS (2020) (0)
- Plasma KIM-1 is associated with clinical outcomes after resection for localized renal cell carcinoma: A trial of the ECOG-ACRIN Research Group (E2805) (2019) (0)
- Targeted Therapy in Melanoma (2015) (0)
- Abstract A082: Single-cell RNA-sequencing of metastatic melanoma identifies a cancer cell-intrinsic program associated with immune checkpoint inhibitor resistance (2019) (0)
- Abstract 4881: Molecular screening of patients with FGFR alterations for phase 1 (ph1) study with the selective FGFR inhibitor Debio 1347 (2019) (0)
- The Challenges with Multi-Arm Targeted Therapy Trials (2018) (0)
- Faculty Opinions recommendation of Progression of RAS-mutant leukemia during RAF inhibitor treatment. (2013) (0)
- with combined dabrafenib and trametinib in a phase 1/2 clinical trial (2014) (0)
- The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. (2022) (0)
- Abstract 2446: Real-time molecular imaging of targeted therapies in patient-derived tumor cells by quantitative immunofluorescence microscopy (2012) (0)
- Abstract LB-260: The use of blood-based protein biomarkers to uncover determinants of immunotherapy response in melanoma (2020) (0)
- Author Correction: From genes to drugs: targeted strategies for melanoma (2020) (0)
- Increase in blood pressure with sorafenib exposure: Renal cell carcinoma (RCC) versus other solid tumors. (2013) (0)
- Randomized trial of web-based genetic education versus usual care in advanced cancer patients undergoing tumor genetic testing: Results from the ECOG-ACRIN NCI Community Oncology Research Program (NCORP; EAQ152) COMET trial. (2020) (0)
- 228 Radiological dynamics and resistance types in patients with advanced melanoma treated with anti-PD-1 monotherapy (2020) (0)
- Distinct epigenetic remodelling defines early stress-induced drug tolerance in melanoma (2018) (0)
- PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance (2019) (0)
- The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. (2022) (0)
- Analysis of patient-reported outcomes by disease progression status in patients (pts) with BRAF V600–mutant metastatic melanoma in the COMBI-d and COMBI-v trials (2016) (0)
- Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2. (2023) (0)
- Melanoma Therapeutic St rategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence Graphical (2017) (0)
- Resistance to checkpoint blockade therapy through inactivation of antigen presentation (2017) (0)
- Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma (2018) (0)
- Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts (2018) (0)
- 371PDA Phase 1 PK/PD Study of ASN003, a novel highly selective BRAF and PI3K inhibitor, in patients with advanced solid tumors (2017) (0)
- REDCap-Based Operational Tool to Guide Care Coordination in a Multidisciplinary Cutaneous Oncology Clinic. (2021) (0)
- Organ site-specific radiological responses in anti-PD-1 monotherapy treated advanced melanoma patients. (2019) (0)
- MC13-0075 Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients (2013) (0)
- Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets (2012) (0)
- Correction: Discovery and clinical introduction of first-in-class imipridone ONC201 (2021) (0)
- INV 34 Clinical trials with sorafenib in melanoma: is there evidence to support adjuvant trials? (2007) (0)
- The benefits of publishing negative results (2013) (0)
- VEGFR-targeted therapy. (2005) (0)
- Cancer Therapy : Preclinical Vemurafenib SynergizeswithNutlin-3 toDeplete Survivin and Suppresses Melanoma Viability and Tumor Growth (2013) (0)
- MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603 (2015) (0)
- Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128]. (2021) (0)
- Molecular genetics and targeted therapies for cutaneous melanoma (2006) (0)
- The Cost of Hope: a candid roundtable discussion. (2013) (0)
- mTOR pathway activation in KIT-mutated melanoma with acquired imatinib resistance. (2012) (0)
- Pooled analysis of factors to predict durable clinical outcomes with combination dabrafenib (D) and trametinib (T) across registration trials (2016) (0)
- Abstract LB-428: RAS-independent dimerization of BRAF(V600E) splicing variants promotes resistance to RAF inhibitors (2012) (0)
- FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th2011” (2012) (0)
- Combining genetic analyses and pre-clinical studies in melanoma defines multiple sub-populations with differential responses to targeted therapies (2008) (0)
- Spartalizumab in Combination With Dabrafenib And Trametinib in Advanced BRAF V600–Mutant Melanoma: Efficacy, Safety, and Biomarker Findings in Parts 1 and 2 of COMBI-i (2020) (0)
- Issue information (2013) (0)
- CMET-16. THE ROLE OF SURGICAL RESECTION OF MELANOMA BRAIN METASTASES IN THE IMMUNOTHERAPY ERA (2017) (0)
- PROSPECTIVE High-Throughput Testing of Novel – Novel Combination Therapies for Cancer : An Idea Whose Time Has Come (2016) (0)
- Adjuvant therapy in patients with sarcomatoid RCC: Post hoc analysis from ECOG-ACRIN E2805. (2021) (0)
- The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. (2022) (0)
- Faculty Opinions recommendation of Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. (2009) (0)
- Clinical Utility of a Blood-Based BRAFMutation Assay in Melanoma (2014) (0)
- Abstract CT160: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol EAY131-Z1L (2022) (0)
- Faculty Opinions recommendation of Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. (2012) (0)
- Clinical Outcomes of Patients with Melanoma Brain Metastases Receiving Stereotactic Radiosurgery and Concurrent Ipilimumab or Pembrolizumab (2017) (0)
- Abstract LB-113: MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability inBRAF,NRASandNF1-mutant melanomas (2019) (0)
- Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma (2022) (0)
- Clinical Outcomes of Patients with Melanoma Brain Metastases Receiving Stereotactic Radiosurgery and Concurrent Ipilimumab or Pembrolizumab (2017) (0)
- Evolution of biomarker research in autoimmunity conditions for health professionals and clinical practice. (2022) (0)
- 1226PDFive-year efficacy and safety update from METRIC: Trametinib vs chemotherapy in patients with BRAF V600E/K–mutant advanced or metastatic melanoma (2017) (0)
- microRNA (miRNA) expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy (CP) in metastatic melanoma (MM) treated on the intergroup trial E2603. (2014) (0)
- The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. (2022) (0)
- Analysis of plasma KIM-1 as a biomarker for recurrence risk after resection for localized renal cell carcinoma. (2021) (0)
- Abstract 1182: Patient derived xenograft (PDX) of human melanoma to predict clinical responses (2014) (0)
- Abstract A01: A comprehensive collection of patient derived xenografts of human melanoma with clinical, genomic, and biological characterization (2016) (0)
- Targeting BRAF/MEK in melanoma: new hope or another false dawn? (2007) (0)
- Faculty Opinions recommendation of Reduced melanoma after regular sunscreen use: randomized trial follow-up. (2011) (0)
- PCN40 Healthcare Resource Utilization in Patients Treated with Encorafenib PLUS Binimetinib for BRAF-Mutant Metastatic Melanoma: DATA from Columbus, a Phase 3 Trial in BRAF-Mutant Melanoma (2020) (0)
- Abstract 5201: Elucidating distinct roles for NF1 in melanomagenesis. (2013) (0)
- Abstract A04: Aging microenvironment modulates melanoma invasion and metastasis (2015) (0)
- Abstract 933: Copy number changes are associated withBRAFandNRASmutations and response to treatment with carboplatin, paclitaxel and sorafenib (2014) (0)
- Abstract LB-C05: Early exosome mRNA changes are associated with improved progression free survival of metastatic melanoma patents on ipilimumab: Identification of a novel exosome mRNA signature of ipilimumab response (2015) (0)
This paper list is powered by the following services:
Other Resources About Keith Flaherty
What Schools Are Affiliated With Keith Flaherty?
Keith Flaherty is affiliated with the following schools:
